RBC Capital keeps Merck & Co at Sector Perform with $145 target
RBC Capital reaffirmed its Sector Perform rating and $145 price target for Merck & Co, citing international pricing pressure and limited EPS growth.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
According to Newsmetry API, RBC Capital maintained its Sector Perform rating on Merck & Co shares and kept the price target at $145.00. The target is roughly in line with the stock’s October 9 closing price of $145.60.
The analyst note highlights continued international pricing pressure. Mandatory rebates in Germany are increasing, while new price-volume agreements are affecting key products including Keytruda. Analysts said this environment represents a significant obstacle to the company’s growth as it moves toward 2027.
Management guidance also points to a substantial rise in operating expenses. As a result, analysts expect only modest earnings-per-share growth next year. Higher investment in research and development and marketing has also contributed to the cautious view of the stock.
why it matters
The combination of international pricing pressure, rising expenses and restrained earnings expectations helps explain RBC Capital’s neutral stance. The $145 target is close to the October 9 close of $145.60, indicating little difference between the stated analyst target and the cited market price.
instruments
sources
- RBC Capital maintains Sector Perform rating on Merck & Co, $145 price target — Newsmetry API, 12 October 2026 at 14:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗